BFC Planning’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$550 Hold
250
– – ﹤0.01% 3279
2026
Q2
$742 Hold
250
– – ﹤0.01% 3207
2026
Q1
$775 Hold
250
– – ﹤0.01% 2785
2025
Q4
$1K Buy
250
+125
+100% +$980 ﹤0.01% 2793
2025
Q3
$1.55K Buy
+125
New +$1.91K ﹤0.01% 2538
2025
Q2
– Sell
-125
Closed -$3.7K – 2696
2025
Q1
$3.7K Hold
125
– – ﹤0.01% 2125
2024
Q4
$4.06K Buy
125
+50
+67% +$2.03K ﹤0.01% 2074
2024
Q3
$3.02K Buy
+75
New +$4.02K ﹤0.01% 2175

Other funds holding CANF

BFC Planning's CANF Position: Q3 2026 in Review

BFC Planning held its Can-Fite BioPharma American Depositary Shares (CANF) position steady in Q3 2026 at 250 shares worth $550. The position accounts for ﹤0.01% of the portfolio, ranked #3279.

BFC Planning first reported a position in CANF in Q3 2024 and has held it in 8 quarters since. The position peaked at $4.06K in Q4 2024. 11 funds tracked by Wall St. Rank hold CANF as of Q3 2026.

  • BFC Planning held 250 shares of Can-Fite BioPharma American Depositary Shares worth $550 as of Q3 2026.
  • BFC Planning left its Can-Fite BioPharma American Depositary Shares share count unchanged in Q3 2026.
  • Can-Fite BioPharma American Depositary Shares made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3279 holding.
  • BFC Planning first reported a position in Can-Fite BioPharma American Depositary Shares in Q3 2024 and has held it in 8 quarters since.
  • BFC Planning's Can-Fite BioPharma American Depositary Shares position peaked at $4.06K in Q4 2024.
  • 11 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.